The Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF) launched its landmark study, the Parkinson\u2019s Progression Markers Initiative (PPMI), in 2010 to better understand Parkinson\u2019s disease (PD) and advance new treatments. Since then, the study has changed how research is done and what scientists know about the brain. It is a cornerstone of our understanding of disease and has heavily influenced clinical trials.
\nToday, PPMI is entering its most ambitious era yet and growing its in-clinic study recruitment from 1,400 to 4,000 volunteers across nearly 50 clinical sites in 12 countries by year-end 2023. Participants contribute biological samples and undergo assessments to characterize Parkinson\u2019s risk, onset and progression.
\nWe are currently screening new potential volunteers:
\n\u2022\tPeople diagnosed with Parkinson\u2019s in the past two years and who are not yet taking medication
\nOR
\n\u2022\tPeople age 60 and older who do not have Parkinson’s, but are living with certain risk factors, including:
\n\uf0a7\tA parent, sister, brother or child with Parkinson\u2019s
\n\uf0a7\tA genetic mutation linked to Parkinson\u2019s (GBA, LRRK2, SNCA, PRKN, PINK1)
\n\uf0a7\tActing out dreams while asleep (REM sleep behavior disorder)
\nOR<\/p>\n
\u2022\tPeople with no known connection to Parkinson\u2019s who wish to participate as control volunteers <\/p>\n
Volunteers in Canada interested in enrolling can contact our research coordinators based on their closest location (To get started, contact study staff below).<\/p>\n","protected":false},"featured_media":35784,"template":"","class_list":["post-35781","clinical-trial","type-clinical-trial","status-publish","has-post-thumbnail","hentry"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t